Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
Sign Up to like & getrecommendations! Published in 2022 at "Birth Defects Research"
DOI: 10.1002/bdr2.2091
Abstract: Belimumab is approved for active, autoantibody‐positive systemic lupus erythematosus (SLE) and lupus nephritis, but limited data exist regarding its use in pregnancy. The Belimumab Pregnancy Registry (BPR, GSK Study BEL114256; NCT01532310) was created to evaluate… read more here.
Keywords: belimumab; pregnancy registry; belimumab pregnancy; pregnancy ... See more keywords
Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
Sign Up to like & getrecommendations! Published in 2017 at "Rheumatology International"
DOI: 10.1007/s00296-017-3682-9
Abstract: To describe the characteristics of patients receiving belimumab, overall patterns of systemic lupus erythematosus (SLE) care, clinical outcomes, and changes in glucocorticoid dose following 6 months of therapy with belimumab, and healthcare resource utilization in belimumab… read more here.
Keywords: clinical outcomes; systemic lupus; lupus erythematosus; study ... See more keywords
Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-017-0586-5
Abstract: BackgroundIntravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneous 200-mg weekly administration, which may prove more convenient for patients and improve adherence,… read more here.
Keywords: systemic lupus; belimumab; analysis; lupus erythematosus ... See more keywords
[Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
Sign Up to like & getrecommendations! Published in 2018 at "Annales de dermatologie et de venereologie"
DOI: 10.1016/j.annder.2017.07.008
Abstract: BACKGROUND Belimumab (an anti-BLyS monoclonal antibody) was recently approved for the treatment of systemic lupus erythematosus (SLE). The aim of the study was to describe efficacy and safety of the drug as well as its… read more here.
Keywords: range; treatment; lupus erythematosus; belimumab ... See more keywords
Efficacité du bélimumab dans les lupus érythémateux cutanés réfractaires : cohorte rétrospective de 8 cas
Sign Up to like & getrecommendations! Published in 2019 at "Annales De Dermatologie Et De Venereologie"
DOI: 10.1016/j.annder.2019.09.162
Abstract: Introduction Le belimumab est un anticorps monoclonal anti-BLyS ayant une indication chez les patients adultes atteints de lupus erythemateux systemique (LES) actif malgre un traitement standard. Nous disposons de peu de donnees sur l’efficacite dans… read more here.
Keywords: atteinte cutanee; belimumab; lesions lupus; les lupus ... See more keywords
Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
Sign Up to like & getrecommendations! Published in 2017 at "Autoimmunity reviews"
DOI: 10.1016/j.autrev.2017.01.010
Abstract: Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus Erythematosus (SLE) met their primary outcomes; however, they were not designed to assess the efficacy of belimumab for the treatment of lupus nephritis (LN).… read more here.
Keywords: systemic lupus; systematic review; lupus erythematosus; efficacy belimumab ... See more keywords
Belimumab slows organ damage progression
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Rheumatology"
DOI: 10.1038/s41584-019-0176-z
Abstract: To assess the efficacy of long-term treatment with belimumab, a post-hoc longitudinal study has used propensity score matching to compare patients from the BLISS long-term extension study who received belimumab (and standard of care) with… read more here.
Keywords: damage progression; belimumab; organ damage; damage ... See more keywords
Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Renal Failure"
DOI: 10.1080/0886022x.2023.2207671
Abstract: Abstract Background Belimumab is the first biological agent approved for the treatment of systemic lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not clear. We conducted this meta-analysis and systematic… read more here.
Keywords: belimumab; meta analysis; therapy; efficacy ... See more keywords
Belimumab for the treatment of pediatric patients with lupus nephritis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2178297
Abstract: ABSTRACT Introduction The FDA approved the anti-BAFF monoclonal antibody, belimumab, in 2011 for adult systemic lupus erythematosus (SLE), in 2019 for pediatric SLE, in 2020 for adult lupus nephritis (LN), and in 2022 for pediatric… read more here.
Keywords: sle; belimumab; lupus nephritis; systemic lupus ... See more keywords
Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2017.1371592
Abstract: ABSTRACT Introduction: Loss of B cell tolerance is a hallmark feature of the pathogenesis of Systemic Lupus Erythematosus (SLE). Recent advances in B cell therapy have focused on targeted therapy aimed at inhibiting B cell… read more here.
Keywords: subcutaneous intravenous; intravenous belimumab; systemic lupus; treatment ... See more keywords
E081 Effectiveness of intravenous belimumab in patients with systemic lupus erythematosus at a UK tertiary referral centre
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.330
Abstract: Belimumab was approved in the United Kingdom (UK) in 2016 as add-on therapy for patients with auto-antibody positive systemic lupus erythematosus (SLE) and high disease activity refractory to standard treatment. Data regarding the effectiveness of… read more here.
Keywords: belimumab; selena sledai; systemic lupus; lupus erythematosus ... See more keywords